Science Pool

Detecting Vanoxerine Arrhythmia in Human iPSC-Derived Cardiomyocytes

Vanoxerine is a multi-ion channel blocker. For this reason, it was developed as a therapy for atrial fibrillation. However, in Phase III trials, 11.5% of patients developed torsades de pointes. Using MEA and human iPSC-derived cardiomyocytes, it was possible to detect this cardiotoxic liability. 

In this poster, we focus on:

  • the use of MEA and human iPSC-derived cardiomyocytes to detect vanoxerine arrhythmias
  • the time dependent effect of vanoxerine cardiotoxicity
  • the ADME properties of vanoxerine which may impact on its cardiotoxic effect

Read our poster to learn more about our research!

Sounds interesting?
Enter your details below to continue reading…

By clicking on ‘Continue’ I agree that my data is being transferred to the Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our Privacy Policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Join our community

Discover the exclusive benefits on offer if you join our community.